Medpace Holdings, Inc. $MEDP Shares Sold by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. trimmed its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 76.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 870 shares of the company’s stock after selling 2,830 shares during the period. Jefferies Financial Group Inc.’s holdings in Medpace were worth $543,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in MEDP. Illinois Municipal Retirement Fund lifted its position in shares of Medpace by 31.3% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 8,652 shares of the company’s stock worth $5,400,000 after purchasing an additional 2,061 shares during the last quarter. Lido Advisors LLC boosted its stake in Medpace by 13.3% during the 3rd quarter. Lido Advisors LLC now owns 1,031 shares of the company’s stock valued at $644,000 after purchasing an additional 121 shares during the period. New York Life Investment Management LLC boosted its stake in Medpace by 13.0% during the 3rd quarter. New York Life Investment Management LLC now owns 3,354 shares of the company’s stock valued at $2,094,000 after purchasing an additional 385 shares during the period. Gen Wealth Partners Inc bought a new stake in Medpace during the 3rd quarter valued at approximately $38,000. Finally, Nemes Rush Group LLC boosted its stake in Medpace by 8.5% during the 3rd quarter. Nemes Rush Group LLC now owns 649 shares of the company’s stock valued at $405,000 after purchasing an additional 51 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Medpace news, CEO August J. Troendle sold 21,966 shares of the company’s stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $625.47, for a total value of $13,739,074.02. Following the completion of the transaction, the chief executive officer owned 338,225 shares of the company’s stock, valued at $211,549,590.75. This represents a 6.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel Stephen P. Ewald sold 1,245 shares of the company’s stock in a transaction that occurred on Thursday, October 29th. The shares were sold at an average price of $690.00, for a total value of $859,050.00. Following the completion of the transaction, the general counsel directly owned 19,098 shares of the company’s stock, valued at approximately $13,177,620. This trade represents a 6.12% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 306,539 shares of company stock valued at $191,774,429 over the last three months. 20.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

MEDP has been the topic of a number of research analyst reports. UBS Group raised their target price on Medpace from $673.00 to $700.00 and gave the company a “neutral” rating in a report on Friday, October 23rd. Barclays upped their price target on Medpace from $625.00 to $675.00 and gave the stock an “equal weight” rating in a report on Friday, October 23rd. Weiss Ratings raised Medpace from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. Truist Financial increased their price objective on Medpace from $609.00 to $633.00 and gave the company a “hold” rating in a research report on Friday, October 23rd. Finally, BMO Capital Markets raised their price objective on shares of Medpace from $600.00 to $670.00 and gave the stock a “market perform” rating in a research note on Monday, October 26th. Three investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $649.27.

Get Our Latest Report on MEDP

Medpace Stock Performance

NASDAQ:MEDP opened at $653.94 on Monday. The firm’s 50-day moving average is $629.52 and its 200-day moving average is $533.79. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $693.97. The company has a market cap of $18.29 billion, a price-to-earnings ratio of 36.25, a PEG ratio of 2.54 and a beta of 1.12.

Medpace (NASDAQ:MEDP – Get Free Report) last announced its quarterly earnings data on Wednesday, October 21st. The company reported $4.84 EPS for the quarter, beating analysts’ consensus estimates of $4.44 by $0.40. Medpace had a net margin of 18.24% and a return on equity of 99.76%. The business had revenue of $716.00 million during the quarter, compared to analyst estimates of $714.47 million. During the same quarter in the prior year, the business earned $3.86 earnings per share. The firm’s revenue for the quarter was up 8.5% on a year-over-year basis. Equities analysts predict that Medpace Holdings, Inc. will post 18.06 EPS for the current year.

Medpace Company Profile

(Free Report)

Medpace Holdings, Inc. is a global contract research organization (CRO) that provides clinical development services to the biotechnology, pharmaceutical and medical device industries. Founded in 1992 and headquartered in Cincinnati, Ohio, the company works with clients developing treatments and medical products across a range of therapeutic areas. Medpace offers services spanning the clinical development process, including clinical trial planning and management, regulatory affairs, clinical laboratory testing, data management, biostatistics, medical writing and pharmacovigilance.

See Also

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.